Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study
Buisson A et.al.; Aliment Pharmacol Ther. 2024 Feb;59(4):526-534
Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease
Roblin X et.al.; J Crohns Colitis. 2023 Nov 2:jjad188
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
Smith PJ et.al.; Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1143-1156.
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial
Constantin A et.al.; Rheumatology (Oxford). 2023 Aug 1;62(8):2838-2844
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
D’Haens et.al.; Clinical Drug Investigation 2023 Apr;43(4):277-288
Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study
Smith et.al.; Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
Peyrin‑Biroulet et.al.; BMC Gastroenterology 2022 Jun 8;22(1):291
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series
Baraliakos X et.al.; Clin Case Rep. 2022 Jan 20;10(1):e05205.
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series
Vijayan S et.al.; Clin Case Rep. 2022 Jan 13;10(1):e05233
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study
Buisson A et.al.; Aliment Pharmacol Ther. 2024 Feb;59(4):526-534
Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease
Roblin X et.al.; J Crohns Colitis. 2023
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
Smith PJ et.al.; Expert Rev Clin Immunol.
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial
Constantin A et.al.; Rheumatology (Oxford). 2023 Aug
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
D’Haens et.al.; Clinical Drug Investigation 2023 Apr;43(4):277-288
Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study
Smith et.al.; Journal of Crohn's and Colitis,
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
Buisson et.al.; Clinical Gastroenterology and Hepatology 2023
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
Peyrin‑Biroulet et.al.; BMC Gastroenterology 2022 Jun 8;22(1):291
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
Westhovens et.al.; Rheumatology 2021;60:2277–2287